Genomic Valley Biotech Limited shareholders have been invited to tender up to 7,94,170 equity shares, representing 26.00% of the company's voting share capital, in a mandatory open offer priced at ₹30 per share. This announcement follows the acquisition of a 46.06% stake by Pankaj Grover and Abhisek Gupta from the existing promoter.

The open offer was triggered under Regulation 3(1) and Regulation 4 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The underlying transaction involved a Share Purchase Agreement executed on October 19, 2026, between the acquirers and Promoter Seller Mr. Yogesh Agrawal. Under this agreement, the acquirers purchased 14,07,000 equity shares, representing 46.06% of the voting capital, for a total consideration of ₹4.22 crore.

Transaction structure and acquirer details

The acquirers, Pankaj Grover and Abhisek Gupta, did not hold any pre-transaction stake in the target company. Post-acquisition, their combined holding stands at 46.06%. The mandatory open offer is intended to provide an exit opportunity to public shareholders who were not part of the negotiated deal.

The offer is unconditional regarding minimum acceptance levels. The total aggregate consideration payable to public shareholders upon full acceptance of the open offer is estimated at ₹2.38 crore. The consideration will be paid in cash.

Offer specifics and timeline

The Detailed Public Statement (DPS) is scheduled to be published in newspapers within five working days of the Public Announcement, i.e., on or before October 27, 2026. The DPS will contain comprehensive details regarding the financial arrangements, background of the offer, and statutory approvals.

What the numbers show

A key observation in this transaction is the alignment between the negotiated price and the open offer price. Both the promoter sale and the mandatory open offer are pegged at ₹30 per share. This uniformity suggests that the acquirers are not offering a premium to public shareholders over the price paid to the exiting promoter, potentially indicating a valuation consensus among all parties or a lack of competitive bidding pressure in the market at the time of the agreement.

Genomic Valley Biotech has secured regulatory approval to extend the deadline for holding its Annual General Meeting (AGM) for FY26. The Registrar of Companies (ROC), Haryana granted a three-month extension, pushing the new deadline to December 31, 2026.

The original statutory deadline for the AGM was September 30, 2026, as mandated under Section 96 of the Companies Act, 2013. The company applied for the extension on August 26, 2026, citing health reasons of the promoter as the primary ground for delay.

Regulatory Approval Details

The ROC approved the request vide its letter dated August 30, 2026, under Section 96(1) of the Companies Act, 2013. The order explicitly grants an extension of three months but advises the company to ensure strict compliance with statutory provisions in the future.

The company informed the BSE Limited of this development on August 31, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Yogesh Agrawal, Managing Director, signed the intimation letter.

What the Numbers Show

The reliance on promoter health as the sole justification for delaying a statutory corporate governance milestone highlights potential concentration risk in decision-making authority. While the extension resolves the immediate compliance breach, the ROC’s advisory note suggests heightened scrutiny may be applied to future filings from the entity. No financial performance data was disclosed in this filing.